CompletedPhase 2

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Japan15 participantsStarted 2008-01

Plain-language summary

The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.

Who can participate

Age range20 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with genotype 1b chronic hepatitis C * Patients naive to the concomitant medications with interferon Exclusion Criteria: * Patients diagnosed with decompensated cirrhosis * Patients diagnosed with positive HBs antigen in the test

What they're measuring

Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration

Timeframe: 24 Weeks After Completion of Drug Administration (dosing period is 24 Weeks) or drug withdrawal. The subjects were assessed at 24 weeks following the last dose of study drug.

Trial details

NCT IDNCT00621296

SponsorTanabe Pharma Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-02

Results submitted2012-09-19

View on ClinicalTrials.gov More Hepatitis C trials